Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study
Douglas R. Adkins(Washington University in St. Louis), Peter Oppelt(Washington University in St. Louis), Jessica Ley(Washington University in St. Louis), Noha N. Salama(Cairo University), Kathryn Trinkaus(Washington University in St. Louis), Marilyn J. Siegel(Mallinckrodt (United States)), Paul Mehan, Xuntian Jiang(Washington University in St. Louis), Barry A. Siegel(Washington University in St. Louis), Farrokh Dehdashti(Washington University in St. Louis)
Cited by 27
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial
|The Lancet Oncology|2013|748
NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018
|Journal of the National Comprehensive Cancer Network|2018|632
NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022
|Journal of the National Comprehensive Cancer Network|2022|532